Share
27,908 Posts.
lightbulb Created with Sketch. 1797
clock Created with Sketch. 06/08/20
18:23
Share
Originally posted by ejwalk
↑
I think RAP fundamentals r good low over head no debt ...the key product is rapdx ...this quarters numbers r important.. but guidance is more important..if rap can do 30000 tests and guide higher that to me is the passing grade .. the sleepcheck product is fun ..good for branding ..and if it could earn 500k a year in profit would be great ..but it's a side show ..the next big driver is a eu contract ...teledoc signs a mou we r on are way to the 1 dollar party .. don't think we will see any big move tell after the quarterly....if usage is taken up and lots of tests r happening ..say 30000 plus .. then a takeover could happen ..but only after the first or second quarter...
Expand
Chronic respiratory management for ashtma and COPD is also a massive market......IMO, SleepCheck can easily earn a few million globally as an initial screening tool for OSA given it's only $8 to download, even cheaper in USD and EURO given the currency conversion.
Last edited by
AlCp :
06/08/20
